Sun Pharma’s UNLOXCYT receives NCCN Category 2A recommendation for laCSCC EP News Bureau Oct 21, 2026 The recommendation adds to UNLOXCYT’s Category 2A designation for metastatic cutaneous squamous cell carcinoma, assigned in 2025
Sun Pharma’s UNLOXCYT (cosibelimab-ipdl) for aCSCC available in US EP News Bureau Jan 16, 2026 Sun Pharma announced UNLOXCYT (cosibelimab-ipdl) is now available in the US for healthcare professionals to prescribe for adults…
Sun Pharma receives US FDA label update approval for UNLOXCYT EP News Bureau Nov 26, 2025 Sun Pharmaceutical announced the US Food and Drug Administration (FDA) approved an updated label for UNLOXCYT (cosibelimab-ipdl)…
